OncoHost Email Format
Hospitals and Health CareIsrael, Israel51-200 Employees
OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. OncoHost’s proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphet® NSCLC test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.